Vertex Pharmaceuticals Inc (VRTX)

VRTX (NASDAQ:Drugs) EQUITY
$122.15
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | VRTX Avg Daily Volume: 1,628,800
Last Update: 05/05/15 - 4:00 PM EDT
Volume: 0
YTD Performance: 6.31%
Open: $0.00
Previous Close: $122.15
52 Week Range: $62.41 - $137.50
Oustanding Shares: 242,088,884
Market Cap: 30,768,361,432
6-Month Chart
TheStreet Ratings Grade for VRTX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 8 8 8
Moderate Buy 1 1 1 1
Hold 10 10 10 9
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.17 2.11 2.11 2.06
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -40.61
Price Earnings Comparisons:
VRTX Sector Avg. S&P 500
-40.61 0.00 28.64
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
15.59% 84.04% 237.61%
GROWTH 12 Mo 3 Yr CAGR
Revenue -52.10 -0.59 -0.25
Net Income 0.00 -19.01 0.00
EPS 0.00 -23.43 0.00
Earnings for VRTX:
EBITDA -0.64B
Revenue 0.58B
Average Earnings Estimates
Qtr (06/15) Qtr (09/15) FY (12/15) FY (12/16)
Average Estimate $-0.74 $-0.35 $-1.92 $4.06
Number of Analysts 12 11 10 12
High Estimate $-0.60 $0.05 $-1.19 $7.91
Low Estimate $-0.90 $-0.87 $-3.31 $0.57
Prior Year $-0.79 $-0.57 $-2.93 $-1.92
Growth Rate (Year over Year) 6.75% 38.12% 34.54% 311.81%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Bullish
Apr 30, 2015 | 7:49 AM EDT
VRTX estimates were raised through 2016, Leerink Partners said. Orkambi should drive near-term growth. Outperform rating and new $150 p...
Biotech companies are saying, "I do."
Teva bid highlights M&A action in health care sector.
Teva bid highlights M&A action in health care sector.
Bullish
Apr 10, 2015 | 7:29 AM EDT
VRTX was initiated with a Buy rating, Canaccord Genuity said. $150 price target. Company has an attractive pipeline, strong balance she...
Even the second-tier biotechs are taking off.
Here are healthcare stocks of all shares and sizes with strong charts.
Bullish
Oct 13, 2014 | 7:55 AM EDT
VRTX was upgraded from Neutral to Overweight, Piper Jaffray said. $125 price target. Expect combination approvals in 2015.

Look Past the Indecision Real Money Pro($)

We got the rally we were looking for -- so now what?
Watch the momentum names, which were the biggest positive today.

Columnist Conversations

Not only a mega acquisition of Salesforce (CRM) by Microsoft (MSFT) can save the market from declines across t...
I have added across the board and aggressively to my long exposure in this sector.
The powerful surge that followed UPS's April 28th earnings report has hit a wall. Shares jumped over 3.4%...
GDP
After the wider than expected Trade Deficit Goldman Sachs has reduced their 1Q2015 Real GDP tracking estimate ...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.